Company / Capital Expenditures
Rapport Therapeutics, Inc. Capital Expenditures History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$2.4M
FY2024
5-year range
$1.6M / $2.4M
FY2023-FY2024
Trend
+47.0%
vs FY2023
Sector context
#91 of 194
Health Care
What the data says
At $2M, Rapport Therapeutics, Inc.'s capital expenditures ranks #91 of 194 in the Health Care sector.
Based on SEC 10-K filings.
$2M in FY2024.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#91 of 194 in Health CareTop 47% of 194This company $2.4M Sector average $117.5M
▼
-98.0% below sector average
Key checks
Key Insights
- In FY2024, capital expenditures increased 47.0% year-over-year.
- Ranks #91 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.4M | +47.0% |
| FY2023 | $1.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026